Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Amortization of Deferred Charges (2021 - 2025)

Historic Amortization of Deferred Charges for Heron Therapeutics (HRTX) over the last 5 years, with Q3 2025 value amounting to $2000.0.

  • Heron Therapeutics' Amortization of Deferred Charges fell 9622.64% to $2000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $161000.0, marking a year-over-year decrease of 2259.62%. This contributed to the annual value of $210000.0 for FY2024, which is 194.17% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Amortization of Deferred Charges is $2000.0, which was down 9622.64% from $53000.0 recorded in Q2 2025.
  • Heron Therapeutics' 5-year Amortization of Deferred Charges high stood at $55000.0 for Q3 2023, and its period low was $2000.0 during Q3 2025.
  • Moreover, its 5-year median value for Amortization of Deferred Charges was $51000.0 (2023), whereas its average is $47055.6.
  • Per our database at Business Quant, Heron Therapeutics' Amortization of Deferred Charges surged by 16315.79% in 2022 and then tumbled by 9622.64% in 2025.
  • Heron Therapeutics' Amortization of Deferred Charges (Quarter) stood at $50000.0 in 2021, then changed by 0.0% to $50000.0 in 2022, then rose by 2.0% to $51000.0 in 2023, then rose by 3.92% to $53000.0 in 2024, then tumbled by 96.23% to $2000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $2000.0 for Q3 2025, versus $53000.0 for Q2 2025 and $53000.0 for Q1 2025.